CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 50 enrolled
Drug / intervention
Adapalene 0.3% / BPO 2.5% geldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02932267
NCT02932267Phase 3Completed
CompareCT.gov

Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide 2.5% in Moderate to Severe Acne in Dark Skin Phototype Subjects

Galderma R&D·interventional·Posted Oct 13, 2016·Updated Feb 18, 2021

In Brief

A Phase 3 clinical trial evaluating Adapalene 0.3% / BPO 2.5% gel for Acne Vulgaris. Completed, enrolled 50 participants across 3 sites in 3 countries.

Detailed Summary

This is a multicenter open-label, prospective study in subjects with dark skin from one of the 3 ethnic/race backgrounds: Asian, Latin American and Black/African-American and with moderate to severe acne vulgaris on the face. All eligible subjects will receive Adapalene 0.3% - BPO 2.5% gel (Epiduo Forte/TactuPump Forte) once daily on whole face. The purpose of this trial is to evaluate subject reported outcomes with the combination of Adapalene 0.3% - BPO 2.5%, Epiduo Forte / TactuPump Forte gel, after 16 weeks of treatment of moderate to severe acne in dark skin phototypes (IV to VI).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesMauritius, Singapore, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 13, 2016
Enrollment StartFeb 2, 2017
Primary CompletionJan 10, 2018
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 9.7 years ago

Interventions

Adapalene 0.3% / BPO 2.5% geldrug

Epiduo Forte / Tactupump gel to be applied once a daily at bed time on entire face during 16 weeks